Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Tirzepatide is a 39-amino-acid synthetic peptide that co-activates the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. GLP-1R activation enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central satiety pathways; GIP receptor agonism augments insulin secretion, improves adipose tissue lipid handling, and may blunt GLP-1-mediated nausea — producing greater A1C and weight-loss effects than selective GLP-1 agonists.
The SURPASS program established efficacy in type 2 diabetes, including SURPASS-2 (Frias et al., NEJM 2021), in which tirzepatide was superior to semaglutide 1 mg for A1C reduction and body weight. The SURMOUNT-1 obesity trial (Jastreboff et al., NEJM 2022) demonstrated up to approximately 20.9% mean body-weight reduction at 15 mg over 72 weeks. SURMOUNT-OSA (Malhotra et al., NEJM 2024) showed large reductions in apnea-hypopnea index in obstructive sleep apnea with obesity, supporting the 2024 FDA indication. The SUMMIT trial (Packer et al., NEJM 2025) demonstrated a lower risk of cardiovascular death or worsening heart failure in HFpEF with obesity.
Typical Dose
2.5–15 mg
Range
2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly (titrated every 4 weeks per FDA label)
Frequency
1x/week (subcutaneous; abdomen, thigh, or upper arm — rotate sites)
Route
SubQ
Duration
Chronic (ongoing while clinically indicated; half-life ~5 days)
Reconstitution
Pre-filled single-dose pen (Mounjaro/Zepbound) or compounded vial
Notes
Per FDA labels (Mounjaro and Zepbound): start 2.5 mg SC once weekly as a non-therapeutic initiation dose, then increase to 5 mg after 4 weeks. If additional glycemic or weight-loss effect is needed, titrate in 2.5 mg increments every 4 weeks to a maximum of 15 mg once weekly. Zepbound maintenance doses for obesity are 5, 10, or 15 mg weekly; SURMOUNT-OSA used the maximum tolerated dose of 10 or 15 mg weekly. Inject into the abdomen, thigh, or upper arm; rotate sites. Missed doses may be taken within 4 days (96 hours); otherwise skip and resume the weekly schedule. When combined with insulin or sulfonylureas, consider reducing those agents to lower hypoglycemia risk.
Aggregated from 255 lab-verified Certificates of Analysis uploaded directly by 1 verified lab. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
COAs
255
Verified labs
1
Avg purity
99.70%
±1.52%
Endotoxin tested
32%
Tested by
These biomarkers are commonly tracked to assess response and safety. Run baseline labs before starting, mid-cycle labs halfway through, and post-cycle labs 1–2 weeks after the final dose.
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs